|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Adiponectin levels are high in cases of diabetic nephropathy, but it remains unclear whether these high levels are a cause or a consequence of the disease.
|
20083470 |
2010 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adiponectin rs2241766T/G and rs17300593G/A rather than rs1501299G/T and rs266729C/G polymorphisms were associated with the risk of DN in T2DM, especially in the Caucasian population.
|
24825737 |
2015 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy.
|
29462574 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin protects against the development of albuminuria in rodent experiments and patients with diabetic kidney disease.
|
29894207 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin exhibits its biological effects through adiponectin receptors (AdipoR1 and AdipoR2), which are distributed in the kidneys, and activation of those receptors could prevent or ameliorate diabetic nephropathy.
|
30135333 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin (ADP) may hold promise as a biomarker for diabetic nephropathy (DN).
|
30557306 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin improves diabetic nephropathy by inhibiting necrotic apoptosis.
|
31572480 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A comprehensive association analysis of 24 single-nucleotide polymorphisms (SNPs) in the adiponectin gene was performed for type 2 diabetes and diabetic nephropathy in African Americans.
|
19056609 |
2009 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression and dysfunction of adiponectin and the cognate receptors are involved in diabetes and diabetic kidney disease (DKD), whereas angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) alleviate diabetic albuminuria and prevent development of DKD through upregulation of adiponectin expression.
|
28870804 |
2017 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Elevation of serum adiponectin and CD146 levels in diabetic nephropathy.
|
17490776 |
2007 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we identified the binding sites for transcriptional factors in the adiponectin promoter region and also evaluated the association between adiponectin promoter polymorphisms and diabetic nephropathy (DN) in T1D patients.
|
18599322 |
2009 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we focus on the role of glomerular hypertrophy in the pathogenesis of DN and discuss the role of adiponectin in its prevention.
|
31048658 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, adiponectin over-expression in STZ rats decreased markers of endothelial dysfunction, a feature of diabetic nephropathy disease progression.
|
21521713 |
2011 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that 11 genetic variants within or near VEGFA, CCR5, CCL2, IL-1, MMP9, EPO, IL-8, ADIPOQ and IL-10 showed significant positive association with diabetic nephropathy.
|
25280384 |
2014 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, there was an association between ADIPOQ -11391A allele with increased DN risk (OR = 1.186, 95% CI: 1.051-1.338, p = 0.006).
|
24344808 |
2014 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Renin-angiotensin-aldosterone system blockers, adiponectin receptor agonists, and PPAR agonists (e.g., tesaglitazar, thiazolidinediones, fenofibrate), which increase plasma adiponectin levels and adiponectin receptors expression, may be potential therapeutic drugs for the treatment of DKD.
|
28402446 |
2017 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.
|
18496510 |
2008 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.
|
29330340 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The LPD prevented the progression of diabetic status; this effect may have been associated with the reduction of FW and the elevation of plasma FGF21 and HMW adiponectin, as well as UCP1 expression in BAT, resulting in suppression of diabetic nephropathy.
|
29507597 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The minor allele of rs3865188 was associated with lower adiponectin levels (P = 0.006). rs11646213 [odds ratio (OR) 1.47; 95% confidence interval (CI) 1.18-1.85; P = 0.0009] and rs3865188 (OR 0.71; 95% CI 0.57-0.90; P = 0.004) were associated with baseline prevalence of established/advanced DN.
|
28499019 |
2017 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The overall significance for this variant (nominal P = 0.011) suggests that ADIPOQ might be involved in the development of diabetic nephropathy.
|
17065357 |
2006 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study aims to evaluate the association of the ACDC genetic variation in T1D and diabetic nephropathy (DN).
|
17189871 |
2007 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study aims to examine the association of tumor necrosis factor-α (TNF-α) g.-308 G > A and adiponectin (ADIPOQ) g. + 45 T > G gene polymorphisms in type 2 diabetes (T2D) and its microvascular complications diabetic retinopathy (DR) and diabetic nephropathy (DN).
|
24655058 |
2014 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study provides evidence that MCF2L2, ADIPOQ and SOX2 genetic polymorphisms have effects on the resistance of DN in female T1D patients, and suggests that the linkage with DN in chromosome 3q may be explained by the cumulated genetic effects.
|
20667095 |
2010 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate the therapeutic effects and the underlying mechanisms of adiponectin in early DN.
|
24816832 |
2014 |